(NASDAQ: BCDA) Biocardia's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.72%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 63.77%.
Biocardia's earnings in 2026 is -$7,339,000.On average, 4 Wall Street analysts forecast BCDA's earnings for 2026 to be -$9,728,181, with the lowest BCDA earnings forecast at -$10,533,565, and the highest BCDA earnings forecast at -$8,742,647. On average, 4 Wall Street analysts forecast BCDA's earnings for 2027 to be -$7,952,402, with the lowest BCDA earnings forecast at -$8,604,884, and the highest BCDA earnings forecast at -$7,153,074.
In 2028, BCDA is forecast to generate -$6,099,415 in earnings, with the lowest earnings forecast at -$5,934,403 and the highest earnings forecast at -$6,199,331.